Targeting melanoma with NT157 by blocking Stat3 and IGF1R signaling.
Flashner-Abramson E, Klein S, Mullin G, Shoshan E, Song R, Shir A, Langut Y, Bar-Eli M, Reuveni H, Levitzki A.
Flashner-Abramson E, et al.
Oncogene. 2016 May 19;35(20):2675-80. doi: 10.1038/onc.2015.229. Epub 2015 Jun 29.
Oncogene. 2016.
PMID: 26119932